To perform a meta-analysis evaluating the efficacy of H2-receptor antagonists in functional (nonulcer) dyspepsia.
The authors do not report the method used to assess validity, or how the validity assessment was performed. [A: Randomisation, blinding, use of placebo-controls and number of patients enrolled in each study were assessed; those studies which did not meet the pre-defined study design criteria were excluded. Validity was assessed independently by two authors and any disagreements were resolved through discussion.]
Data extraction
A data collection form was developed and was used to record methodological criteria such as study design, duration of treatment, drug regimen, age and gender of the patients, study protocol, and the outcome measures used to determine efficacy. For each study, the log odds ratio and a 95% confidence interval (CI) was calculated.
The authors do not state how many of the reviewers performed the data extraction. [A: Data extraction was performed collectively by all three authors.]
Methods of synthesis
How were the studies combined? The results were combined by a meta-analysis, using the random=effects method of DerSimonian and Laird (see Other Publications of Related Interest). The overall odds ratio (OR) was reported, along with the 95% confidence interval (CI) and P-values. Publication bias was not assessed.
How were differences between studies investigated?
Before attempting to combine the results from different studies, the authors tested the homogeneity of the ORs using the Q-statistic.
Results of the review
Twenty-two randomised, double-blind, placebo-controlled trials with a total of 2,959 patients were included in the review,. Fourteen trials used a parallel group design, 2 used a two-period crossover design, and 6 used a six-period multicrossover design. The sample sizes of the individual studies ranged from 21 to 509. The number of studies that could be used to pool the results for the different outcome measures varied: 7 studies (940 patients) were used for global assessment by the patient of the treatment effect; 5 studies (1,299 patients) were used for complete relief of pain; and 4 studies (589 patients) were used for improvement in pain.
H2-receptor antagonists were found to be superior to placebo in 15 of the 22 studies. However, the number of studies that could be used for pooling the results varied for the different outcome measures.
Global assessment: only 7 studies provided sufficient data to calculate the number of patients who were improved; these 7 studies were combined in a meta-analysis. A moderate beneficial effect of H2-receptor antagonists was demonstrated for global assessment of dyspepsia symptoms with an OR of 1.48 (95% CI: 0.94, 2.32). The P-value for the homogeneity test was 0.047, suggesting that there was significant heterogeneity among the studies. Results in favour of H2-blockers were seen in the studies that did not state that patients with a prior peptic ulcer disease were excluded. Similarly, in 4 of the 5 studies in favour of H2-blockers, oesophagitis was not clearly stated as a reason for exclusion from the study. The 2 studies that excluded both previous peptic ulcers and oesophagitis did not demonstrate a benefit of active treatment over placebo.
Epigastric pain: based on 7 studies, the OR for complete relief of pain for drug-versus placebo-treated patients was 1.81 (95% CI: 1.15, 2.84, P<0.01). The P-value for the homogeneity test was 0.017, suggesting that there was significant heterogeneity among the studies. The OR for improvement of pain was 2.33 (95% CI: 1.63, 3.32, P<0.0001). The P-value for the homogeneity test was 0.67, suggesting that for this outcome measure there was no significant heterogeneity among the studies. Thus, showing a clear benefit of H2-antagonists for the relief or improvement of epigastric pain. As with the global assessment outcome measure for absence or improvement of epigastric pain, studies that excluded previous peptic ulcer disease did not show a benefit of the H2-receptor antagonists. 
